Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (744 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Nerve fibers that are capable of rapidly conducting impulses away from the neuron cell body.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Axon.
Where it fits in the MeSH classification
- Broader topics
- Nerve Fibers; Cell Surface Extensions
- Narrower topics
- Axon Initial Segment; Neurites; Presynaptic Terminals; Schaffer Collaterals; Growth Cones; Mossy Fibers, Hippocampal
- See also
- Axotomy
Research landscape
PubMed indexes 77,934 records tagged with the MeSH heading “Axons” (counts retrieved 2026-10-29). 7,472 of them (9.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 32,447 records.
Reviews account for 6,775 records (8.7%) and meta-analyses for 22. Randomized controlled trials number 55 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 32,447 |
| 2000-2009 | 19,963 |
| 2010-2019 | 18,052 |
| 2020 onward | 7,472 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 6,775 | 8.7% |
| Meta-analyses | 22 | 0.0% |
| Randomized controlled trials | 55 | 0.1% |
Method: PubMed query "Axons"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in neuroscience
Neuroscience draws on tools with different strengths: cellular and animal work can manipulate circuits directly, while human imaging and electrophysiology observe the living brain at lower resolution. Small imaging studies are prone to false positives, and findings in animals do not always carry over to people. Clinical neurology and psychiatry rely on trials and cohort studies whose outcomes are often symptom scales. Check the species, the sample size, how the outcome was measured and whether results were replicated.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Axonal injury is a targetable driver of glioblastoma progression | 2025 | Research article Design not recorded in structured metadata | 26 | cc by PMID 40836081 · DOI · PMC12507684 |
| Annexin A6 membrane repair protein protects against amyloid-induced dystrophic neurites and tau phosphorylation in Alzheimer's disease model mice | 2025 | Research article Design not recorded in structured metadata | 15 | cc by PMID 40411591 · DOI · PMC12103342 |
| Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer's disease | 2025 | Research article Design not recorded in structured metadata | 13 | cc by PMID 40781079 · DOI · PMC12334674 |
| Microtubules in the axon are GDP bound but adopt a stable GTP-like expanded state | 2026 | Research article Design not recorded in structured metadata | 8 | cc by PMID 41951886 · DOI · PMC13095656 |
Axonal injury is a targetable driver of glioblastoma progression [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Glioblastoma (GBM) is an aggressive and highly therapy-resistant brain tumour1,2.
- Closing excerpt
- Thus, targeting the tumour-induced injury microenvironment may supress progression from latent to advanced disease, thereby providing a potential strategy for GBM interception and control.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (147 words)
Glioblastoma (GBM) is an aggressive and highly therapy-resistant brain tumour1,2. Although advanced disease has been intensely investigated, the mechanisms that underpin the earlier, likely more tractable, stages of GBM development remain poorly understood. Here we identify axonal injury as a key driver of GBM progression, which we find is induced in white matter by early tumour cells preferentially expanding in this region. Mechanistically, axonal injury promotes gliomagenesis by triggering Wallerian degeneration, a targetable active programme of axonal death3, which we show increases neuroinflammation and tumour proliferation. Inactivation of SARM1, the key enzyme activated in response to injury that mediates Wallerian degeneration4, was sufficient to break this tumour-promoting feedforward loop, leading to the development of less advanced terminal tumours and prolonged survival in mice. Thus, targeting the tumour-induced injury microenvironment may supress progression from latent to advanced disease, thereby providing a potential strategy for GBM interception and control.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40836081 · DOI · PMC12507684
Annexin A6 membrane repair protein protects against amyloid-induced dystrophic neurites and tau phosphorylation in Alzheimer's disease model mice [2]
Abstract reading summary — source excerpts
- Opening excerpt
- In Alzheimer's disease, accumulation of amyloid-β (Aβ) peptide is thought to cause formation of neurofibrillary tangles composed of hyperphosphorylated tau protein, which correlates with neuronal loss and cognitive impairment, but the mechanism linking Aβ and tau pathologies is unknown.
- Closing excerpt
- Overexpression of annexin A6 reduces dystrophic neurites and phospho-tau accumulation, suggesting that annexin A6-mediated membrane repair may represent a novel therapeutic approach for AD.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (303 words)
In Alzheimer's disease, accumulation of amyloid-β (Aβ) peptide is thought to cause formation of neurofibrillary tangles composed of hyperphosphorylated tau protein, which correlates with neuronal loss and cognitive impairment, but the mechanism linking Aβ and tau pathologies is unknown. Dystrophic neurites, which surround Aβ plaques and accumulate phosphorylated tau and other proteins, may play a role in seeding and spreading of pathologic tau. Here, we investigate the novel hypothesis that improved membrane repair capacity decreases dystrophic neurite formation by protecting axons from Aβ-induced membrane damage. Using a ratiometric calcium sensor and a FRET-based calpain cleavage sensor, we demonstrate that dystrophic neurites in 5XFAD mice have elevated resting calcium levels and calpain activity because of putative membrane damage. Annexin A6, a plasma membrane repair in muscle and neurons, is present at plasma membrane of neurons and dystrophic neurites in murine and human brains. Overexpression of annexin A6 in brains of 5XFAD mice decreased size and quantity of dystrophic neurites and accumulation of phospho-tau181, an early biomarker of amyloid pathology. Phospho-tau231, another early amyloid biomarker, and phosphorylated of tau kinases, c-jun N-terminal kinase (JNK) and Calmodulin Kinase II (CaMKII) accumulate in dystrophic neurites in the brains of amyloid pathology mice and humans with AD, suggesting that dystrophic neurites are sites of active tau phosphorylation. Overexpression of dominant-negative annexin A6 in 5XFAD mice increased dystrophic neurites and phospho-tau181. Intracerebral injection of recombinant annexin A6 in 5XFAD and APP-NLGF knock-in mice resulted in localization of recombinant A6 to membranes of dystrophic neurites, suggesting therapeutic potential of recombinant annexin A6 for AD. In conclusion, dystrophic neurites have Aβ-induced membrane damage characterized by calcium elevation, calpain activation, and accumulation of tau kinases and phosphorylated tau. Overexpression of annexin A6 reduces dystrophic neurites and phospho-tau accumulation, suggesting that annexin A6-mediated membrane repair may represent a novel therapeutic approach for AD.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40411591 · DOI · PMC12103342
Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer's disease [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Alzheimer's disease (AD) often begins with non-cognitive symptoms such as olfactory deficits, which can predict later cognitive decline, though the mechanisms remain unclear.
- Closing excerpt
- Our findings reveal a mechanism linking early LC damage to hyposmia in AD, suggesting olfactory testing and neurocircuit imaging for early diagnosis and enable timely therapeutic intervention for Alzheimer's disease.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (148 words)
Alzheimer's disease (AD) often begins with non-cognitive symptoms such as olfactory deficits, which can predict later cognitive decline, though the mechanisms remain unclear. Pathologically, the brainstem locus coeruleus (LC), the main source of the neurotransmitter noradrenalin (NA) modulating olfactory information processing is affected early. Here we show early and distinct loss of noradrenergic input to the olfactory bulb (OB) coinciding with impaired olfaction in an AD mouse model, before appearance of amyloid plaques. Mechanistically, OB microglia recognize and phagocytose LC axons. Reducing phagocytosis genetically preserves LC axons and olfaction. Prodromal AD patients display elevated TSPO-PET signals in the OB, similarly to AppNL-G-F mice. We further confirm early LC axon degeneration in post-mortem OBs in patients with early AD. Our findings reveal a mechanism linking early LC damage to hyposmia in AD, suggesting olfactory testing and neurocircuit imaging for early diagnosis and enable timely therapeutic intervention for Alzheimer's disease.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40781079 · DOI · PMC12334674
Microtubules in the axon are GDP bound but adopt a stable GTP-like expanded state [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Microtubules scaffold cells, supporting signaling and cargo transport.
- Closing excerpt
- Our work provides molecular insights into neurogenesis and has implications for understanding microtubule stability and effector recruitment in neurons.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (146 words)
Microtubules scaffold cells, supporting signaling and cargo transport. They assemble from GTP-tubulin, which hydrolyzes to GDP-tubulin during polymerization. GTP-microtubule lattices are stable; GDP lattices depolymerize rapidly. In vitro, hydrolysis triggers lattice compaction. Lattice spacing regulates motors and microtubule-associated proteins; however, the conformation of tubulin in microtubules in cells is unknown. Here, we present the atomic-resolution cryo-electron microscopy structure of human microtubules in situ, in the axons of human cortical neurons derived from induced pluripotent stem cells (iPS cells). Our 2.7-Å-resolution reconstruction delineates bound water molecules and reveals that axonal microtubules adopt an expanded GTP-like lattice, despite being GDP bound. Using cryo-electron tomography and power spectrum analysis, we find that, unlike in axons, microtubules in undifferentiated iPS cells are compacted. Therefore, lattice expansion is part of neuronal differentiation. Our work provides molecular insights into neurogenesis and has implications for understanding microtubule stability and effector recruitment in neurons.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41951886 · DOI · PMC13095656
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article The Biology of Regeneration Failure and Success After Spinal Cord Injury [5]
- Research article Spinal cord injury: molecular mechanisms and therapeutic interventions [6]
- Research article α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis [7]
- Research article Regulation of axonal regeneration after mammalian spinal cord injury [8]
- Research article NODDI in clinical research [9]
- Research article Axonal transport and neurological disease [10]
References
- Clements M, Tang W, Florjanic Baronik Z, Simpson Ragdale H, Oria R, Volteras D, et al.. Axonal injury is a targetable driver of glioblastoma progression. . 2025. PMID 40836081 · DOI · PMC12507684
- Sadleir KR, Gomez KP, Edwards AE, Patel AJ, Ley ML, Khatri AW, et al.. Annexin A6 membrane repair protein protects against amyloid-induced dystrophic neurites and tau phosphorylation in Alzheimer's disease model mice. . 2025. PMID 40411591 · DOI · PMC12103342
- Meyer C, Niedermeier T, Feyen PLC, Strübing FL, Rauchmann BS, Karali K, et al.. Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer's disease. . 2025. PMID 40781079 · DOI · PMC12334674
- Zehr EA, Sun S, Sarbanes SL, Roll-Mecak A. Microtubules in the axon are GDP bound but adopt a stable GTP-like expanded state. . 2026. PMID 41951886 · DOI · PMC13095656
- Tran AP, Warren PM, Silver J. The Biology of Regeneration Failure and Success After Spinal Cord Injury. Physiol Rev. 2018. PMID 29513146 · DOI · PMC5966716
- Hu X, Xu W, Ren Y, Wang Z, He X, Huang R, et al.. Spinal cord injury: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023. PMID 37357239 · DOI · PMC10291001
- Mehra S, Sahay S, Maji SK. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. Biochim Biophys Acta Proteins Proteom. 2019. PMID 30853581 · DOI
- Zheng B, Tuszynski MH. Regulation of axonal regeneration after mammalian spinal cord injury. Nat Rev Mol Cell Biol. 2023. PMID 36604586 · DOI
- Kamiya K, Hori M, Aoki S. NODDI in clinical research. J Neurosci Methods. 2020. PMID 32814118 · DOI
- Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G. Axonal transport and neurological disease. Nat Rev Neurol. 2019. PMID 31558780 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.